Eukaryotic Expression Systems Market is Expected to Clock a Notable A CAGR of 8.2%and Reach USD 7.44 billion by 2032

Market Overview: The global market for eukaryotic expression systems was valued at USD 3.66 billion in 2022 and is projected to reach USD 7.44 billion by 2032, with an estimated compound annual growth rate (CAGR) of 8.2% over the forecast period. Key drivers of market growth include the increasing prevalence of chronic diseases, a growing demand for biopharmaceuticals, and advancements in gene therapy technology.

Biopharmaceuticals, such as monoclonal antibodies, vaccines, and recombinant proteins, are increasingly used to treat chronic illnesses like cancer, diabetes, and autoimmune disorders, and they are produced using eukaryotic expression systems. The need for biopharmaceuticals is expected to rise in tandem with the increasing prevalence of these diseases, bolstering market revenue.

The expansion of the market for eukaryotic expression systems is also anticipated due to advancements in gene therapy technology. These systems play a crucial role in producing the proteins required for gene therapy, a technique that introduces genetic information into cells to treat or prevent diseases. Increased interest in gene therapy is expected to drive demand for eukaryotic expression systems.

Get a sample copy of the Eukaryotic Expression Systems Market report:

Moreover, the market’s revenue growth is further stimulated by the increasing partnerships and collaborations between pharmaceutical companies and research institutions, as well as greater investments in research and development (R&D) activities. Eukaryotic expression systems are vital for developing innovative biopharmaceuticals, and pharmaceutical companies are allocating significant resources to R&D to create these products. The collaboration between pharmaceutical companies and research institutions is expected to accelerate the development of novel biopharmaceuticals and drive market growth.

Nevertheless, the high production costs associated with using eukaryotic expression systems to create biopharmaceuticals represent a significant challenge that may impede market revenue growth. The complex and time-consuming production process can lead to higher costs, potentially limiting the widespread adoption of eukaryotic expression systems, particularly in less developed countries where affordability is a significant concern.

Furthermore, the availability of alternative expression systems and a lack of awareness among end-users about the advantages of eukaryotic expression systems may also hinder revenue growth. Despite the various benefits offered by eukaryotic expression methods, such as higher protein yields and improved protein quality compared to alternatives, a lack of awareness could limit their adoption.

Government Regulations: Various regulatory agencies around the world have established guidelines and requirements for the use of eukaryotic expression systems in the development of therapeutic products. These agencies include:

  1. The U.S. Food and Drug Administration (FDA)
  2. The European Commission
  3. The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan
  4. The World Health Organization (WHO)
  5. The International Conference on Harmonization (ICH)

Key Insights:

Types of Expression Systems:

  • In 2022, mammalian expression systems dominated the eukaryotic expression systems market in terms of revenue due to their ability to produce complex proteins and human-like proteins with reduced risk of immunological reactions. The demand for these systems is driven by the need for biopharmaceuticals to treat diseases like cancer, diabetes, and autoimmune disorders.
  • The yeast expression systems segment is projected to experience the highest revenue CAGR throughout the forecast period. These systems are increasingly used to produce recombinant proteins for biopharmaceuticals, food and beverages, and biofuels, supported by advancements in genetic engineering techniques.


  • In 2022, the therapeutic proteins segment accounted for the largest share of market revenue. The demand for therapeutic proteins is driven by the increasing prevalence of chronic diseases, and eukaryotic expression systems are preferred for their ability to produce high-quality, complex proteins with proper folding and post-translational modifications.
  • The vaccines segment is expected to witness the fastest revenue growth, particularly in the production of recombinant subunit vaccines for infectious diseases and cancer immunotherapy.
  • The antibodies segment is also expected to experience significant growth, with eukaryotic expression systems being widely used for the production of monoclonal antibodies for cancer and autoimmune disease treatment.
  • The research segment is expected to grow steadily, as eukaryotic expression systems are used in basic and applied research for various applications, including structural biology, enzymology, and drug discovery.
  • The “others” segment, which includes gene therapy and industrial enzymes, is projected to witness substantial growth, driven by the use of eukaryotic expression systems in gene therapy and industrial applications.

Regional Outlook:

  • North America leads the eukaryotic expression systems market in terms of revenue, driven by a high concentration of pharmaceutical and biotechnology companies, strong R&D activities, and favorable government initiatives in the United States and Canada.
  • Europe is expected to hold a significant market share, with countries like Germany, France, and the UK contributing to market growth. The regulatory environment and government initiatives in Europe support biotechnology research and development.
  • The Asia Pacific region is projected to achieve the fastest revenue CAGR, driven by investments in the biotechnology sector, increasing demand for biopharmaceuticals, and rising research and development activities in countries like China, Japan, and India.
  • Latin America and the Middle East & Africa are also anticipated to witness significant market growth due to investments in biotechnology, increasing demand for biopharmaceuticals, and growing research and development activities.

Key Market Players: Notable companies in the eukaryotic expression systems market include Thermo Fisher Scientific, Lonza Group Ltd., Merck KGaA, QIAGEN N.V., Promega Corporation, Agilent Technologies, Takara Bio, GenScript Biotech Corporation, Bio-Rad Laboratories, and BD Biosciences. These companies are actively engaged in strategic developments and new product launches to strengthen their positions in the market.

Strategic Developments:

  • In 2021, Lonza Group Ltd. expanded its manufacturing capacity for gene and cell therapies in the United States to meet the increasing demand for these therapies.
  • In 2020, Thermo Fisher Scientific, Inc. acquired Qiagen N.V. to enhance its position in the eukaryotic expression systems market by leveraging Qiagen’s expertise in sample and assay technologies.
  • In 2019, Merck KGaA launched the ExpiCHO-S™ eukaryotic expression system, designed to increase protein yield and reduce production time.

New Product Launches:

  • In 2021, Lonza Group Ltd. introduced the GS piggyBac™ eukaryotic expression system, designed to enhance the yield of complex proteins and reduce production time.
  • In 2020, Merck KGaA launched the ExpiSf™ eukaryotic expression system, aimed at improving protein production in insect cells.
  • In 2019, Thermo Fisher Scientific, Inc. launched the Gibco™ ExpiCHO™ eukaryotic expression system, designed to increase protein yield and reduce production time.

This comprehensive report provides historical data, revenue forecasts, company rankings, competitive landscape

Explore Trending Reports:

Levulinic Acid Market-

Corn Fiber Market-

Release Agents Market-

Request a customization of the report:

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @

Browse Latest Blogs:

Browse Latest Press Release: